Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer

BJU International
Ravi A MadanWilliam L Dahut

Abstract

To determine the safety and clinical efficacy of two anti-angiogenic agents, bevacizumab and lenalidomide, with docetaxel and prednisone. Eligible patients with metastatic castration-resistant prostate cancer enrolled in this open-label, phase II study of lenalidomide with bevacizumab (15 mg/kg), docetaxel (75 mg/m(2) ) and prednisone (10 mg daily). Docetaxel and bevacizumab were administered on day 1 of a 3-week treatment cycle. To establish safety, lenalidomide dosing in this combination was escalated in a conventional 3 + 3 design (15, 20 and 25 mg daily for 2 weeks followed by 1 week off). Patients received supportive measures including prophylactic pegfilgrastim and enoxaparin. The primary endpoints were safety and clinical efficacy. A total of 63 patients enrolled in this trial. Toxicities were manageable with most common adverse events (AEs) being haematological, and were ascertained by weekly blood counts. Twenty-nine patients (46%) had grade 4 neutropenia, 20 (32%) had grade 3 anaemia and seven (11%) had grade 3 thrombocytopenia. Despite frequent neutropenia, serious infections were rare. Other common non-haematological grade 3 AEs included fatigue (10%) and diarrhoea (10%). Grade 2 AEs in >10% of patients included ano...Continue Reading

References

Mar 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kai-Uwe BelgeLöms Ziegler-Heitbrock
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Oct 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·John M L EbosRobert S Kerbel
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Jun 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Charlie T GarnettJames W Hodge
Mar 13, 2010·Science·Takumi ItoHiroshi Handa
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yang-Min NingWilliam L Dahut
Jun 18, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anil BagriGreg D Plowman
Dec 6, 2011·International Journal of Cancer. Journal International Du Cancer·Niels F AndersenAnnette J Vangsted
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Kevin KellyEric J Small
Oct 10, 2012·Proceedings of the National Academy of Sciences of the United States of America·Yuhui HuangMark C Poznansky
Dec 12, 2012·The New England Journal of Medicine·Charles J RyanUNKNOWN COU-AA-302 Investigators
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emmanuel S Antonarakis, Mario A Eisenberger
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
Sep 4, 2014·The New England Journal of Medicine·Emmanuel S AntonarakisJun Luo
Sep 10, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ethan BaschKatherine S Virgo
Oct 30, 2014·The New England Journal of Medicine·Tomasz M Beer, Bertrand Tombal
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Feb 18, 2015·Cancer Chemotherapy and Pharmacology·Eirini PanoiliaGregory Sivolapenko
Aug 6, 2015·The New England Journal of Medicine·Christopher J SweeneyRobert S DiPaola

❮ Previous
Next ❯

Citations

Mar 21, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Athina Mavrou, Sebastian Oltean
Apr 18, 2016·Cancer Chemotherapy and Pharmacology·Rabih SaidApostolia M Tsimberidou
May 22, 2018·Expert Opinion on Biological Therapy·Vittore CeredaMario Roselli
Jun 4, 2019·International Journal of Molecular Sciences·Zsombor Melegh, Sebastian Oltean
Oct 4, 2017·Endocrine-related Cancer·Gianmarco LeoneMassimo Di Maio
Aug 28, 2020·Cancers·Chandrani SarkarDebanjan Chakroborty
May 15, 2021·Expert Opinion on Pharmacotherapy·Vincent ChauJeanny B Aragon-Ching

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.